Global Pharmaceuticals & Biotech Top Stock Picks from Analysts

Molecure

Market Cap: zł133.3m

A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland.

SCYNEXIS

Market Cap: US$36.4m

A biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States.

OnKure Therapeutics

Market Cap: US$36.4m

A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers.

Senti Biosciences

Market Cap: US$36.1m

A clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases.

Arecor Therapeutics

Market Cap: UK£26.6m

A clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom.

Mersana Therapeutics

Market Cap: US$35.5m

A clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs.

CASI Pharmaceuticals

Market Cap: US$35.3m

A biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally.

Dyadic International

Market Cap: US$34.6m

A biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally.

CollPlant Biotechnologies

Market Cap: US$33.2m

A regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.

Rani Therapeutics Holdings

Market Cap: US$33.1m

Operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.

Proteomics International Laboratories

Market Cap: AU$49.9m

Operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia.

Medicus Pharma

Market Cap: US$32.6m

A biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets.

Kairos Pharma

Market Cap: US$32.2m

A clinical-stage biopharmaceutical company, develops therapeutics for cancer patients.

Lipum

Market Cap: SEK 299.1m

A biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden.

Poltreg

Market Cap: zł114.3m

A biotechnology company, researches and develops therapies for autoimmune diseases.

Rubicon Organics

Market Cap: CA$43.0m

Engages in the production, processing, and sale of organic cannabis for the recreational and medical-use markets in Canada and internationally.

Reviva Pharmaceuticals Holdings

Market Cap: US$30.4m

A biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases.

Nicox

Market Cap: €25.9m

Operates as an ophthalmology company in France and internationally.

Vidac Pharma Holding

Market Cap: €25.8m

An investment holding company, engages in the discovery and development of medicines for oncologic and dermatologic diseases.

Camp4 Therapeutics

Market Cap: US$29.8m

A clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases.

Cynata Therapeutics

Market Cap: AU$45.1m

Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.

BioAtla

Market Cap: US$29.3m

A clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

Tissue Regenix Group

Market Cap: UK£21.4m

A medical technology company, develops and commercializes platform technologies for bone graft substitutes, skin, and soft tissue biologics markets in the United States and internationally.

SynBiotic

Market Cap: €24.5m

Engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety.

Iterum Therapeutics

Market Cap: US$28.2m

A pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States.

Daré Bioscience

Market Cap: US$28.1m

Develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States.

Kezar Life Sciences

Market Cap: US$28.0m

A clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States.

Karolinska Development

Market Cap: SEK 261.5m

A venture capital firm specializing in investments in growth capital, seed stage, and early stage companies.

Initiator Pharma

Market Cap: SEK 258.8m

A clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system.

Clearside Biomedical

Market Cap: US$27.5m

A biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.

Prescient Therapeutics

Market Cap: AU$41.6m

A clinical stage oncology company, develops drugs for the treatment of various cancers in Australia.

NeuroSense Therapeutics

Market Cap: US$27.1m

A clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally.

GenSight Biologics

Market Cap: €22.8m

A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.

Syntara

Market Cap: AU$40.7m

Operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia.

MIRA Pharmaceuticals

Market Cap: US$26.3m

Operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.

Theranexus Société Anonyme

Market Cap: €22.4m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.